2009-011799-31-IE

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011799-31

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the following primary and secondary objectives in patients with moderate-to-severe Alzheimer’s disease (AD) and behavioral and psychiatric symptoms: Co-Primary Objectives • To evaluate the efficacy of Dimebon as compared to placebo on a measure of behavior, the Neuropsychiatric Inventory (NPI); • To evaluate the efficacy of Dimebon as compared to placebo on a measure of self-care and daily function, the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (severe) (ADCS ADLsev).


Critère d'inclusion

  • Alzheimer's disease